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Abstract
Background: Local HIV epidemiology data are critical in determining the suitability of a population for HIV vaccine efficacy
trials. The objective of this study was to estimate the prevalence and incidence of, and determine risk factors for HIV
transmission in a rural community-based HIV vaccine preparedness cohort in Masaka, Uganda.
Methods: Between February and July 2004, we conducted a house-to-house HIV sero-prevalence survey among consenting
individuals aged 18–60 years. Participants were interviewed, counseled and asked to provide blood for HIV testing. We then
enrolled the HIV uninfected participants in a 2-year HIV sero-incidence study. Medical evaluations, HIV counseling and testing,
and sample collection for laboratory analysis were done quarterly. Sexual risk behaviour data was collected every 6 months.
Results: The HIV point prevalence was 11.2%, and was higher among women than men (12.9% vs. 8.6%, P=0.007). Risk
factors associated with prevalent HIV infection for men were age ,25 years (aOR=0.05, 95% CI 0.01–0.35) and reported
genital ulcer disease in the past year (aOR=2.17, 95% CI 1.23–3.83). Among women, being unmarried (aOR=2.59, 95% CI
1.75–3.83) and reported genital ulcer disease in the past year (aOR=2.40, 95% CI 1.64–3.51) were associated with prevalent
HIV infection. Twenty-one seroconversions were recorded over 2025.8 person-years, an annual HIV incidence of 1.04% (95%
CI: 0.68–1.59). The only significant risk factor for incident HIV infection was being unmarried (aRR=3.44, 95% CI 1.43–8.28).
Cohort retention after 2 years was 87%.
Conclusions: We found a high prevalence but low incidence of HIV in this cohort. HIV vaccine efficacy trials in this
population may not be feasible due to the large sample sizes that would be required. HIV vaccine preparatory efforts in this
setting should include identification of higher risk populations.
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Introduction
Thebest long-termhope tocontroltheHIV/AIDSpandemicis a
safe, effective, and affordable preventive vaccine [1]. HIV vaccine
efficacy clinical trials must be performed in African populations
where the burden of HIV remains greatest [2] and the need for an
effective vaccine most pressing. However, before such trials are
initiated, preparatory studies that include estimates of HIV
prevalence and incidence need to be conducted in potential study
populations [3]. HIV incidence data are necessary to ensure that
planned HIV vaccine efficacy trials will be adequately powered to
detect a difference between immunized and placebo recipients. The
number of volunteers participating in a phase III trial depends
mainly on the incidence of HIV infections in the study population
with fewer volunteers required where HIV incidence is high [1].
Since 2003, the MRC/UVRI Uganda Research Unit on AIDS,
in collaboration with the International AIDS Vaccine Initiative
(IAVI), has been conducting Vaccine Preparatory Studies (VPS) to
determine the suitability of potential populations for future HIV
vaccine efficacy trials should suitable candidate vaccines become
available. The objective of the current study was to determine the
HIV prevalence, incidence, and risk factors for HIV infection in a




The study was conducted in three neighboring rural commu-
nities in Masaka district, Uganda. The communities were selected
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3to participate based on the following criteria; experience of HIV
prevention research, previously high HIV prevalence [4] and,
presence of a health facility from which some study activities could
be conducted. We assumed the HIV prevalence to be between
10% and 20% based on historical data [4], and estimated that a
maximum sample size of 1,600 would be required to provide an
HIV prevalence estimate with 95% confidence interval width of
no more than 2 percentage points.
Procedures
HIV sero-prevalence study. The HIV sero-prevalence
survey was performed between February and July 2004. First, a
census of all residents in the three communities was conducted.
Using the census lists, individuals were then contacted in person
and invited to participate in the house-to-house survey study. The
survey was conducted one community at a time, until a sufficient
sample size had been achieved. Individuals were enrolled if they
were aged 18–60 years, clinically healthy and willing to give
written informed consent, be tested for pregnancy (females),
undergo sexual behavior risk assessment, be counseled and tested
for HIV and receive test results.
At enrolment, study information was given, written informed
consent obtained and an interviewer administered questionnaire
used to collect information on demographics, vaccine knowledge,
sexual risk behaviors, medical history and 5 ml of blood drawn for
HIV serology. Female participants were asked to provide a urine
sample for pregnancy testing. Individuals who were not found at
home during the first visit were revisited at least twice to give them
a chance to participate. One follow up visit was conducted 1–4
weeks after enrolment to provide HIV test results, conduct post-
test and risk reduction counseling and referrals for support and
care as necessary.
HIV sero-incidence study. The HIV sero-incidence study
was conducted between October 2004 and April 2007. Individuals
who were found to be HIV uninfected during the sero-prevalence
study were invited for screening and enrolment at one of three
government health centres closest to their home. Enrollment was
offered to healthy HIV negative males and females aged 18–60
years, who were able and willing to give written informed consent,
be followed quarterly for 2 years, complete interviewer admini-
stered questionnaires on HIV risk factors, HIV comprehension,
willingness to participate in HIV vaccine trials, undergo repeated
HIV voluntary counseling and testing (VCT) and receive the
results, and for females, pregnancy testing.
At enrolment, study information was given, written informed
consent obtained and information on demographics and sexual
risk behaviors collected using an interviewer administered
questionnaire. A medical history was taken, a physical
examination performed and VCT done. 15 ml of blood was
drawn for HIV and syphilis serology and storage of plasma and
serum.
At each quarterly follow up visit, a medical history was taken, a
symptom directed physical examination performed and HIV VCT
conducted. Collection of specimens and laboratory tests were
conducted as for the enrolment visit.
Sexual risk behavior data were collected every 6 months and
included data on reported symptoms of reproductive tract
infections (RTIs), number of sexual partners, casual sex partners,
condom use, alcohol consumption and HIV risk perception.
Interim visits were conducted to perform HIV VCT for
presumed exposure to HIV, obtain laboratory test results from
previous visits, assess and treat illness, and in response to volunteer
requests or tracing efforts.
Ethics statement
The VPS study protocols and informed consent documents
were reviewed and approved by the Uganda Virus Research
Institute Science and Ethics Committee and the Uganda National
Council of Science and Technology. Prior to enrolment, a detailed
discussion of the study information was conducted with each
Table 1. Baseline demographic characteristics of 1663 HIV prevalence study participants in Masaka, Uganda.
All participants Men Women
n % n % n % Chi-value P-value
Total 1663 100 650 100 1013 100
Mean age (SD) 33.3 (11.3) 34 (11.2) 32.9 (11.3) t-test 0.051
Age group
18–24 441 26.5 151 23.2 290 28.6 5.94 0.051
25–34 566 34 230 35.4 336 33.2
$35 656 39.5 269 41.4 387 38.2
Current marital status
Married 1,150 69.2 447 68.8 703 69.4 0.07 0.787
Unmarried" 513 30.8 203 31.2 310 30.6
Education level
None 256 15.4 63 9.7 193 19.1 33.34 ,0.001
Primary school 1,187 71.4 478 73.5 709 70
$Secondary school 220 13.2 109 16.8 111 11
Occupation
Subsistence farmer 1,327 79.8 430 66.2 897 88.6 123.17 ,0.001
Other 336 20.2 220 33.9 116 11.5
"Unmarried: separated, widowed and never married.
doi:10.1371/journal.pone.0020684.t001
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were provided with outpatient free medical care for common
illnesses, HIV risk reduction counseling and condoms at all study
visits. HIV infected participants were provided with free CD4/
CD8 T-cell counts and those eligible referred for initiation of ART
available at no cost. Referrals were also made as necessary for
prevention of mother-to-child HIV transmission (PMTCT) and
other HIV related care services. Seroconverters in the HIV
incidence study were in addition given information about and
offered participation in an ongoing acute HIV infection study.
Laboratory methods
Determine (Abbot Laboratories, Japan) rapid test was used to
screen for HIV antibodies. HIV positive results were confirmed by
performing two parallel ELISAs (Vironostika Uni-Form II Ag/Ab,
BioMerieux, Netherlands & Murex HIV.2.O, Murex Biotech Ltd.,
UK). Western blot testing (Genetic systems, Biorad Laboratories)
was used to resolve discrepant ELISA results. HIV testing was
repeated after 2–4 weeks on a fresh specimen if the Western blot
test was indeterminate. Syphilis testing was done using the rapid
plasma reagin (RPR) test (Biotec). RPR reactive specimens were
further tested with the Treponema pallidum Haemaglutination
(TPHA) assay (Biotec). Participants were considered to have
serological syphilis infection if they tested positive for TPHA and
RPR with RPR titres of 1:4 or greater. ßhCG reagent strips (Bayer
Multistix 10SG) were used for urine pregnancy testing.
Statistical analysis
Data were recorded in MS Access and analysed in Stata 10
(StataCorp, College Station, Texas, USA). Participant character-
istics were summarized using frequencies and percentages for
categorical variables and means and standard deviations for
continuous variables. Chi square and t tests were used to compare
demographic characteristics between men and women. Odds
ratios and their 95% Confidence Intervals (CI) were used to assess
the association between variables and HIV prevalence. Unadjust-
ed (univariable) analyses were conducted and a likelihood ratio test
(LRT) used to screen for variables to be included in the adjusted
(multivariable) model. Variables that reached a significance level
of P,0.1 were selected for inclusion in the multivariable model
based on the theory of conceptual frameworks [5]. Sex and age
were included and retained in the multivariable model as a priori
confounders. Variables were removed from the multivariable
model using a backward elimination type algorithm, retaining
those that remained significant at P,0.05. Predictors of HIV
incidence were determined by fitting unadjusted and adjusted




Participant characteristics. A total of 9,078 individuals,
3,261 (36%) of whom were in the 18–60 year age category, was
listed in the census. Of those aged 18–60 years, 1,977 (60.6%)
were contacted in person and invited to participate in the HIV
sero-prevalence survey, 585 (17.9%) were not at home, 698
(21.4%) were not contacted because a sufficient sample size had
been achieved and one had died. Of those that were contacted,
1,663 (84.1%) consented to participate, 299 (15.1%) refused, and
15 (0.8%) were excluded due to sickness. Among those that
consented to participate; 1,013 (61%) were female, 61% were aged
less than 35 years, 69% were currently married, 80% were
subsistence farmers and only 13% had attained secondary school
or higher education. Compared to men, women were younger
(p=0.051); had no formal education (p,0.001) and were more
likely to be subsistence farmers (p,0.001) (Table 1).
HIV prevalence. The overall HIV point prevalence was
11.2% (95% CI 9.8–12.9). HIV prevalence was significantly
higher among women than men (12.9% vs. 8.6%, P=0.007), and
increased with age peaking early among women (25–34 years) and
later among men ($35 years) (table 2). Unmarried women were
more likely to be HIV infected than those that were currently
married (P,0.001). Also, women who reported two or more
sexual partners in the past year were more likely to be HIV
infected than those who reported only one sexual partner
(P,0.05). Men and women who reported a history of genital
ulcer disease in the past year had higher HIV prevalence than
those who did not.
Age, marital status and a history of genital ulcer disease were
independently associated with prevalent HIV infection (table 3).
Among men, risk of HIV infection was significantly decreased in
the youngest age group i.e. ,25 years (aOR=0.05, 95% CI 0.01–
0.35) and increased in those reporting genital ulcer disease in the
Table 2. Gender stratified HIV prevalence among 1663 study
participants in Masaka, Uganda.
Men Women
n Prevalence(%) n Prevalence (%)
Total 650 8.6 1,013 12.9
Age group
18–24 151 0.7 290 10.3
25–34 230 9.6 336 14.9
$35 269 12.3 387 13.2
Current marital status
Married 447 8.3 703 9.5
Unmarried" 203 9.4 310 20.7**
Level of education
None 63 14.3 193 9.3
Primary school 478 8.2 709 13.8
$Secondary school 109 7.3 111 14.4
Occupation
Subsistence farmer 430 9.1 897 13.4
Other 220 7.7 116 9.5
Sexual partners in the past year
0–1 585 8.2 849 11.5
$2 65 12.3 164 20.1*
Condom use in past year
No 466 8.8 910 12.3
Yes 184 8.2 103 18.5
Genital ulcer disease in past year
No 473 6.8 707 9.8
Yes 177 13.6* 306 20.3**
Genital discharge in past year
No 574 7.8 690 11.6
Yes 76 14.5 323 15.8
"Unmarried: separated, widowed and never married;
*P,0.05,
**P,0.001 by Chi square or Fisher’s exact test.
doi:10.1371/journal.pone.0020684.t002
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unmarried (aOR=2.59, 95% CI 1.75–3.83) and reported genital
ulcer disease in the past year (aOR=2.40, 95% CI 1.64–3.51)
were associated with an increased risk of HIV infection.
HIV incidence study
Participant characteristics. A total of 1,248 individuals
were screened and of these 1,184 (95%) enrolled into the HIV
incidence study. The most common reasons for study ineligibility
were, age above 60 years (26) and failure to comprehend study
information (22). Of those enrolled, 722 (61%) were female, 57%
were younger than 35 years, 71% were currently married and only
14% had attained secondary school or higher education.
A total of 1,029 (87%) participants completed the study. Of the
155 drop-outs, 121 (78.1%) moved from the study area, 13 (8.4%)
lost interest and requested to discontinue participation, 11 (7.1%)
were withdrawn after they were recruited into another VPS
involving HIV discordant couples, 4 (2.6%) could not be
contacted, 3 (1.9%) were terminated due to ill health and 3
(1.9%) died.
Compared with those who completed study follow up, drop-outs
wereyounger(meanage,32vs.35years;p=0.006)withmost (36%)
in the 25–34 year age category, and more likely to have reported
condom use in the past year (18.8% vs. 11.3%; p=0.001) but were
otherwise similar in regard to other baseline characteristics.
HIV incidence. Twenty one participants seroconverted
during 2025.8 person years of follow up, an overall HIV
incidence of 1.04% (95% CI: 0.68–1.59). Women had a lower
annual HIV incidence (0.8%) compared to men (1.41%) although
this difference was not statistically significant (aRR=0.51, 95%
CI 0.21–1.21) (Table 4). The only significant risk factor for
HIV acquisition was being unmarried (aRR=3.44, 95% CI
1.43–8.28).
Discussion
We found a high HIV prevalence (11.2%) but relatively low
incidence (1.04 per 100 person-years) in this rural community-
based HIV vaccine preparedness cohort. The observed HIV
prevalence was higher than the national average of 6.4% [6].
However, this was expected since we purposely selected commu-
nities with previously high HIV prevalence [4] to participate in
this study. The HIV incidence in our study was slightly higher
than that reported in other rural community-based studies in
Table 3. Logistic regression analysis of gender-specific risk factors for HIV infection among 1663 participants in Masaka, Uganda.
Men Women
OR 95% CI aOR 95% CI OR 95% CI aOR 95% CI
Age 1.03* 1.01–1.05 - - 1.01 0.99–1.02 - -
Age group
18–24 0.048* 0.01–0.35 0.05** 0.01–0.35 0.76 0.47–1.23 0.95 0.58–1.57
25–34 0.76 0.43–1.34 0.75 0.42–1.33 1.15 0.75–1.75 1.35 0.87–2.10
$3 5 1111
Current marital status
Married 1 1 1
Unmarried" 1.14 0.64–2.04 - - 2.47* 1.7–3.59 2.59** 1.75–3.83
Level of education
None 1 1
Primary 0.53* 0.24–1.16 - - 1.54* 0.92–2.62 - -
$Secondary 0.48 0.17–1.3 - - 1.64 0.8–3.36 - -
Number of sexual partners in the
past year
0–1 1 1
$2 1.57 0.71–3.48 - - 1.93* 1.25–2.99 - -
Condom use in the past year
No 1 1
Yes 0.92 0.5–1.71 - - 1.61* 0.94–2.75 - -
Reported genital ulcer disease in
past year
N o 1111
Yes 2.16* 1.23–3.79 2.17** 1.23–3.83 2.35* 1.62–3.41 2.40** 1.64–3.51
Reported genital discharge in the
past year
No 1 1
Yes 1.99* 0.98–4.04 - - 1.43* 0.98–2.09 - -
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individuals younger than 18 years in whom HIV incidence rates
are relatively low [9,10].
Consistent with other studies in Sub Saharan Africa
[8,10,11,12], HIV prevalence was higher among women than in
men. This disparity was more marked in the youngest age group
Table 4. Poisson regression analysis of baseline risk factors for incident HIV infection among 1184 participants in Masaka, Uganda.
n (%) Seroconverters/PYO Rate/100 PYO RR (95% CI) LRT P-value aRR (95% CI)
Total 1184 (100) 21/2025.8 1.04
Sex
Male 462 (39) 11/779.9 1.41 1 P=0.198 1
Female 722 (61) 10/1245.9 0.8 0.57 (0.24–1.34) 0.51 (0.21–1.21)
Age (mean, SD) 34 (10.9) 0.99 (0.95–1.02) P=0.523
Age group
18–24 241 (20.4) 2/400.4 0.499 1 P=0.246 1
25–34 434 (36.6) 11/740.6 1.49 2.97 (0.99–13.42) 4.16 (0.90–19.30)
$35 509 (43) 8/884.8 0.9 1.81 (0.38–8.53) 2.09 (0.44–9.97)
Current marital status
Married 835 (70.5) 10/1,439.3 0.69 1 P=0.025 1
Unmarried" 349 (29.5) 11/586.5 1.88 2.7 (1.15–6.36) 3.44 (1.43–8.28)
Level of education
None 154 (13) 1/265.1 0.38 1 P=0.441
Primary 869 (73.4) 17/1495.8 1.14 3.01 (0.4–22.6) -
$Secondary 161 (13.6) 3/264.9 1.13 3 (0.31–8.86) -
Frequency of alcohol
consumption
Does not drink 546 (46.1) 8/921.6 0. 87 1 P=0.294
Once/month 365 (30.8) 5/639.3 0.78 0.9 (0.29–2.75) -
$4 times/month 273 (23.1) 8/464.9 1.72 1.98 (0.74–5.28) -
Number of sexual
partners in the past year
0–1 958 (80.9) 15/1,651.6 0.91 1 P=0.261
$2 226 (19.1) 6/374.2 1.6 1.77 (0.68–4.55) -
Concurrent partners
No 1,056 (89.2) 16/1,814.5 0.88 1 P=0.08
Yes 128 (10.8) 5/211.3 2.37 2.68 (0.98–7.32) -
Condom use in past year
No 841 (74.2) 13/1460.1 0.89 1 P=0.176
Yes 292 (25.8) 8/479.6 1.67 1.87 (0.78–4.52) -
Reported genital ulcer
disease in past year
No 843 (71.2) 13/1450.3 0.9 1 P=0.339
Yes 341 (28.8) 8/575.5 1.39 1.55 (0.64–3.74) -
Reported genital
discharge in past year
No 848 (71.6) 16/1449.8 1.1 1 P=0.633
Yes 336 (28.4) 5/576 0.87 0.79 (0.29–2.15) -
Serological syphilis
Positive 23 (1.9) 0/404.8 0 1
Negative 1,161 (98.1) 21/1985.3 1.06 - - -
Circumcised
No 399 (86.4) 10/678.5 1.47 1 P=0.685
Yes 63 (13.6) 1/101.4 0.99 0.67 (0.09–5.23) -
"Unmarried: separated, widowed and never married; PYO: person-years of observation; RR: rate ratio; aRR: adjusted rate ratio.
doi:10.1371/journal.pone.0020684.t004
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prevalence compared to men. High rates of HIV infection among
young women have been attributed to a higher prevalence of
herpes simplex type II infection [13] and early marriage [14].
Conversely, although men had higher HIV incidence than
women, this difference was not significant. Available literature
on gender-specific HIV transmission risk is inconclusive. Some
studies have reported similar HIV transmission risk in both
genders [6] while in others, HIV incidence was found to be higher
in women compared to men [7,8]. The reasons for these
inconsistent results are not well understood.
Marriage has been reported as risk factor for HIV infection in
sub-Saharan Africa [9,10,11]. However, in our study, marriage
did not increase risk for prevalent HIV infection among men and
was even protective among women. Additionally, unmarried
participants had an increased risk of HIV acquisition compared to
those that were married. This is probably because unmarried
participants engaged in riskier behavior compared to those who
were married. Indeed, unmarried participants in our study were
more likely to report $2 sexual partners in the past year than
those that were married (data not shown). Also, in a population-
based study in the neighboring communities, unmarried men and
women were more likely to report a casual partner in the past year
than their married counterparts [12].
Genital ulcerative disease (GUD) increases susceptibility to HIV
by disrupting the mucosal barrier [13]. In the current study, a
history of GUD in the past year was associated with higher HIV
prevalence. Although the incidence rate of HIV was higher
amongst participants with a history of genital ulcer disease in the
past one year, the association was not statistically significant,
possibly due to the small number of HIV incident cases.
In addition to providing accurate estimates of HIV incidence,
vaccine preparatory studies are necessary to assess recruitment and
retention of volunteers over several years and the willingness of a
population to participate in future efficacy trials [14]. In the
current study, about 87% of participants were retained in follow
up for up to two years. Also, willingness to participate in future
HIV vaccine efficacy trials in this population is high [15].
However, the low HIV incidence observed in this study implies
that vaccine trials in this population would require very large
sample sizes. Large community-based trials would require more
funding than that which has been available [14]. On the other
hand, identification of high-risk groups with higher HIV incidence
in rural African communities with generalized epidemics such as
ours is difficult [16]. Nevertheless, to ensure participation in future
HIV vaccine efficacy trials in these settings, preparedness efforts
should include the identification of high risk sub-populations such
as individuals in discordant couple relationships and commercial
sex workers with higher HIV incidence. The nature of HIV
vaccination programs will to some extent be determined by the
stage of the HIV epidemic [17]. Whereas countries with
concentrated epidemics may target high-risk groups for vaccina-
tion, this approach may not be suitable in countries with
generalised epidemics [17]. Therefore, although targeting high-
risk groups may be practical for evaluating HIV vaccine efficacy in
our setting, it may not be appropriate for future HIV vaccination
programs.
A major limitation of this study is that sexual risk behaviour data
was obtained by self report. We ensured the confidentiality of
participants, and that sexual risk behaviour assessments were
conducted by well trained and experienced interviewers. However,
participants could have under-reported stigmatized behaviours
and over-reported socially acceptable behaviours. Another limita-
tion is that routine laboratory RTI screening was limited to
syphilis serology in the VPS protocol. Laboratory diagnosis of
other RTIs would have allowed for better characterization of the
participants’ HIV risk profile. Selection bias is also a possible
limitation as individuals who did not participate in the study may
have had a different HIV risk profile from those who did. In
particular, individuals with self-perceived high HIV risk may have
refused to or avoided participation in the study, which may have
resulted in underestimation of HIV infection rates. Related to this,
loss to follow up could have resulted in underestimation of HIV
incidence. The most common reason for loss to follow up was out-
migration. Migration has been associated with an increased risk of
HIV infection probably due to higher risk sexual behavior among
those who move [18]. Also, most of the participants who dropped
out of the study were in the 25–34 year age group, a category with
the highest HIV incidence.
In summary, we found a high HIV prevalence but a low HIV
incidence in this rural community-based HIV vaccine prepared-
ness cohort. The low HIV incidence suggests that a vaccine
efficacy trial in this population may not be feasible due to the large
sample size that would be required. Preparatory efforts for future
HIV vaccine efficacy trials in this and similar settings should
include the identification of populations with higher HIV
incidence.
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